HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

BACKGROUND: The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer. METHODS: HER2...

Descripción completa

Detalles Bibliográficos
Autores principales: McAlpine, Jessica N, Wiegand, Kimberly C, Vang, Russell, Ronnett, Bridgett M, Adamiak, Anna, Köbel, Martin, Kalloger, Steve E, Swenerton, Kenneth D, Huntsman, David G, Gilks, C Blake, Miller, Dianne M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803495/
https://www.ncbi.nlm.nih.gov/pubmed/20003286
http://dx.doi.org/10.1186/1471-2407-9-433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803495/
https://www.ncbi.nlm.nih.gov/pubmed/20003286
http://dx.doi.org/10.1186/1471-2407-9-433

Ejemplares similares